An Australian biotech company has engineered a new virus based on cowpox that is able to kill every known type of cancer. Now they are ready for human trials. The treatment called CF33 (below pic) has been found to shrink tumors in mice and it is hoped it will be trialed on Australian breast and other cancer patients early next year. Engineered by US cancer expert Professor Yuman Fong, (below pic) the treatment is being developed by Australia's Imugen, which has licensed the innovation. The so-called “basket study” to be run in Australia and other countries will enrol patients with triple negative breast cancer, melanoma, lung cancer, bladder, gastric and bowel cancer. In other medical news Australian Associate Professor Tom John from the Olivia Newton John Cancer Research Institute recently tested another virus treatment in combination with immunotherapy Keytruda on 11 lung cancer patients and 3 patients saw their tumors shrink. While US scientists have turned the virus that causes the common cold into a treatment to kill brain cancer — in some patients the cancer disappeared for years before returning, in others it shrank the tumors considerably.
That is wonderful news!! Can you imagine how much suffering could be eliminated and so many untimely deaths? It's a totally evil disease.
Just imagine how many people this insidious disease has taken this century alone @Bess Barber. Many great people among them like Walt Disney, Jacquie Kennedy, Jack Lemmon, Steve Jobs, Aretha Franklin, Dr Seuss, Carl Sagan.
Keytruda by itself worked for me (stage 4, inoperable lung cancer). There are some adverse consequences and collateral damage but it beats the alternative.
Adelaide Hospital clinical trial to target and kill cancer cells brings hope to cancer patients More news from my country about our constant battle against the Big C. Adelaide Hospital doctors believe they've made a major breakthrough in cancer treatment, and will conduct clinical trials of a new technology to find, and hopefully destroy, cancer cells. Head of RAH's cancer clinical trials unit, Professor Michael Brown, said the new technique would use antibodies that carry a low dose of radiation to target dead or dying cancer cells. The antibody can act as a diagnostic tool to measure the effectiveness of treatment. "The radiation signal is picked up on a PET scan, so we can see in patients who have received chemotherapy just how well the chemotherapy is killing the cancer cells," Professor Brown said. The trial will first be tested on lung and ovarian cancer patients and later other cancer sufferers.